SIREN : 791452675
XPO PHARMA FRANCE is a French company founded 13 years ago, specialized in the sector Entreposage et stockage non frigorifique. Based in LYON (69006), this company of category GE shows in 2024 a revenue of 847 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 847 457 € | 1 126 755 € | 950 043 € | 735 991 € | 790 265 € | 927 933 € | 832 079 € | 767 738 € | 854 837 € |
| Net income | -115 451 € | 40 659 € | 90 536 € | -76 522 € | -19 138 € | 88 184 € | 29 842 € | 14 381 € | 53 005 € |
| EBITDA | -76 776 € | 85 927 € | 103 707 € | -81 464 € | -21 542 € | 132 499 € | 38 732 € | 31 514 € | 75 964 € |
| Net margin | -13.6% | 3.6% | 9.5% | -10.4% | -2.4% | 9.5% | 3.6% | 1.9% | 6.2% |
In 2024, XPO PHARMA FRANCE achieves revenue of 847 k€. Activity remains stable over the period (CAGR: -0.1%). Significant drop of -25% vs 2023. After deducting consumption (0 €), gross margin stands at 847 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -77 k€, representing -9.1% of revenue. Warning negative scissor effect: despite revenue change (-25%), EBITDA varies by -189%, reducing margin by 16.7 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -115 k€ (-13.6% of revenue), which will impact equity.
847 457 €
847 457 €
-76 776 €
-112 182 €
-115 451 €
-9.0%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 31%. The balance between equity and debt is satisfactory.
0.0%
31.258%
-9.435%
0.0
48.3%
In 2024, the debt ratio of XPO PHARMA FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of XPO PHARMA FRANCE (31.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of XPO PHARMA FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 59.80. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
59.798
-11.739
In 2024, the liquidity ratio of XPO PHARMA FRANCE (59.80) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of XPO PHARMA FRANCE (-11.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 25 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 57 days. Excellent situation: suppliers finance 32 days of the operating cycle (retail model). Overall, WCR represents 25 days of revenue, i.e. 58 k€ to permanently finance. Notable WCR improvement over the period (-64%), freeing up cash.
58 119 €
25 j
57 j
0 j
25 j
Based on 77 transactions of similar company sales
(all years),
the value of XPO PHARMA FRANCE is estimated at
121 832 €
(range 78 837€ - 291 493€).
The price/revenue ratio is 0.14x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 77 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare XPO PHARMA FRANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Entreposage et stockage non frigorifique
The revenue of XPO PHARMA FRANCE in 2024 is 847 k€.
XPO PHARMA FRANCE recorded a net loss in 2024.
The headquarters of XPO PHARMA FRANCE is located in LYON (69006), in the department Rhone.
The tax return of XPO PHARMA FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
XPO PHARMA FRANCE operates in the sector Entreposage et stockage non frigorifique (NAF code 52.10B). See the 'Sector positioning' section above to compare the company with its competitors.